### Highlights of This Issue

**SPECIAL FEATURES**

**CCR 20th Anniversary Commentary**

3  Clinical Cancer Research: The 20th Anniversary

**CCR Translations**

4  Bromodomain Inhibition in Diffuse Large B-cell Lymphoma—Giving MYC a Brake
   Anja Mottok and Randy D. Gascoyne
   See related article, p. 113

7  New, Tolerable γ-Secretase Inhibitor Takes Desmoid Down a Notch
   Dennis P.M. Hughes, Shivaani Kummar, and Alexander J. Lazar
   See related article, p. 60

**CCR New Strategies**

10 New Strategies in Renal Cell Carcinoma: Targeting the Genetic and Metabolic Basis of Disease
   Ramaprasad Srinivasan, Christopher J. Ricketts, Carole Sourbier, and W. Marston Linehan

**Molecular Pathways**

18 Molecular Pathways: Not a Simple Tube—The Many Functions of Blood Vessels
   Brent A. Orr and Charles G. Eberhart

24 Molecular Pathways: Targeting the Kinase Effectors of RHO-Family GTPases
   Tatiana Y. Prudnikova, Sonali J. Rawat, and Jonathan Chernoff

**CANCER THERAPY: CLINICAL**

30 Tadalafil Augments Tumor Specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma

39 Tadalafil Reduces Myeloid-Derived Suppressor Cells and Regulatory T Cells and Promotes Tumor Immunity in Patients with Head and Neck Squamous Cell Carcinoma
   Donald T. Weed, Jennifer L. Vella, Isidirinha M. Reis, Adriana C. De la fuente, Carmen Gomez, Zoukaa Sargi, Ronen Nazarian, Joseph Califano, Ivan Borrello, and Paol Serafini

49 Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial
   Serena Di Cosimo, Siiram Sathyanarayanan, Johanna C. Bendell, Andrés Cervantes, Mark N. Stein, Irene Bratia, Desamparados Roda, Brian B. Haines, Theresa Zhang, Christopher G. Winter, Sharda Iha, Youyuun Xu, Jason Frazier, Richard A. Klinghofer, Ann Leighton-Swayze, Yang Song, Scott Ebbleyhaus, and José Baselga

60 A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral γ-Secretase Inhibitor PF-03084014
   See related commentary, p. 7

68 A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis
   Kim A. Reiss, Joseph M. Herman, Marianna Zahurak, Anthony Brade, Laura A. Dawson, Angela Scardina, Caitin Jofl, Emily Petito, Amy Hacker-Prietz, Robert J. Kinders, Lihua Wang, Alice Chen, Sarah Temkin, Naomi Hori, Lillian L. Sui, and Nilofar A. Azad

77 First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
87 First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors
Geoffrey I. Shapiro, Eunice Kwak, Bruce J. Dezube, Murray Yule, John Aytton, John Lyons, and Danuka Mahadevan

PERSONALIZED MEDICINE AND IMAGING

98 Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients

106 Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Assessment of Angiogenic Treatment Effects in Multiple Myeloma
Maximilian Merz, Judith Ritsch, Christina Kunz, Barbara Wagner, Sandra Sauer, Dirk Hose, Thomas Moehler, Stefan Delorme, Hartmut Goldschmidt, Christian Zechmann, and Jens Hillengass

CANCER THERAPY: PRECLINICAL

113 Inhibition of Bromodomain Proteins for the Treatment of Human Diffuse Large B-cell Lymphoma
Sally E. Trabucco, Rachel M. Gerstein, Andrew M. Evens, James E. Bradner, Leonard D. Shultz, Dale L. Geerter, and Hong Zhang
See related commentary, p. 4

123 Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)
Hridesh Uppal, Estelle Doudement, Kaushiki Mahapatra, Walter C. Darbonne, Daniela Bumbaca, Ben-Quan Shen, Xiaoyan Du, Ola Saad, Kristin Bowles, Steve Olsen, Gail D. Lewis Phillips, Dylan Hartley, Mark X. Sliwkowski, Sandhya Choufani, Dong Dambach, and Vanitha Ramakrishnan

134 The Novel IKK2 Inhibitor LY2409881 Potently Synergizes with Histone Deacetylase Inhibitors in Preclinical Models of Lymphoma through the Downregulation of NF-κB
Changhun Deng, Mark Lipstein, Richard Rodriguez, Xavier O. Jirau Serrano, Christine McIntosh, Wei-Yann Tsai, Andrew S. Wasmuth, Susan Jaken, and Owen A. O’Connor

146 CD99 Triggering in Ewing Sarcoma Delivers a Lethal Signal through p53 Pathway Reactivation and Cooperates with Doxorubicin
Claudia Guezzoni, Valentina Fiori, Mario Terracciano, Maria Cristina Manara, Diego Moricoli, Michela Pasello, Marika Scialla, Giordano Nicoletti, Mara Gellini, Sabrina Dominici, Claudia Chiodoni, Pier Maria Forzani, Pier-Luigi Lollini, Mario P. Colombo, Piero Pici, Maurizio Cianfriglia, Mauro Magnani, and Katia Scollandi

157 Low Expression of the E3 Ubiquitin Ligase CBL Confers Chemoresistance in Human Pancreatic Cancer and Is Targeted by Epidermal Growth Factor Receptor Inhibition
Brian E. Kadera, Paul A. Toste, Nanping Wu, Luyi Li, Andrew H. Nguyen, David W. Dawson, and Timothy R. Donahue

166 Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer
Ryohei Katayama, Yuka Kobayashi, Luc Friboulet, Elisabeth L. Lockerman, Sumie Koike, Alice T. Shaw, Jeffrey A. Engelman, and Naoya Fujita

BIOLOGY OF HUMAN TUMORS

175 Development of a Prognostic Genetic Signature to Predict the Metastatic Risk Associated with Cutaneous Melanoma

184 Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups
Diana M. Merino, Adam Shlien, Anita Villani, Malgorzata Pienkowska, Stephen Mack, Vijay Ramaswamy, David Shih, Ruth Tavieosian, Ana Novokmet, Sanah Choufani, Rina Dvir, Myan Ben-Arush, Brent T. Harris, Eugene I. Hwang, Rishi Lulla, Stefan M. Pfliser, Maria Isabel Achazit, Nada Jabado, Jonathan I. Finlay, Rosanna Weksberg, Cynthia Hawkins, Michael D. Taylor, Uli Tabory, David W. Ellison, Richard J. Gilbertson, and David Malkin
The Ability of Bilirubin in Identifying Smokers with Higher Risk of Lung Cancer: A Large Cohort Study in Conjunction with Global Metabolomic Profiling
Chi-Pang Wen, Fanmao Zhang, Dong Liang, Christopher Wen, Jian Gu, Heath Skinner, Wong-Ho Chow, Yuanqing Ye, Xia Pu, Michelle A.T. Hildebrandt, Maosheng Huang, Chien-Hua Chen, Chao Agnes Hsiung, Min Kuang Tsai, Chwen Keng Tsao, Scott M. Lippman, and Xifeng Wu

Activation of IL6/IGFIR Confers Poor Prognosis of HBV-Related Hepatocellular Carcinoma through Induction of OCT4/NANOG Expression
Te-Sheng Chang, Yu-Chih Wu, Ching-Chi Chi, Wei-Chi Su, Pei-Jium Chang, Kam-Fai Lee, Tao-Hsin Tung, Jui Wang, Jun-Jen Liu, Shui-Yi Tung, Liang-Mou Kuo, Hong-Nerng Ho, Thai-Yen Ling, and Yen-Hua Huang

Effects of BRCA1- and BRCA2-Related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis
Qian Zhong, Hong-Ling Peng, Xia Zhao, Lin Zhang, and Wei-Ting Hwang

LETTERS TO THE EDITOR

Diffusion-Weighted MRI for Lymphoma Staging—Letter
Hugo J.A. Adams and Thomas C. Kwee

Diffusion-Weighted MRI for Lymphoma Staging—Response
Marius E. Mayerhoefer and Markus Raderer

ABOUT THE COVER

The cover shows the results of an unsupervised two-dimensional hierarchical clustering analysis of the 5,000 most variable genes classifying breast tumors into ER+, HER2+, or triple-negative (ER-, PR-, HER2-) subtypes. The analysis was performed on 800 breast tumors obtained from the Karolinska Institutet, Sweden. The RAS gene expression signature was high in the triple-negative subtype and low in the ER+ subtype. For details, see the article by Di Cosimo and colleagues on page 49 of this issue.